Better Together: BioCryst, Idera Merge To Improve Rare Disease Position

A pair of primarily clinical-stage, publicly traded rare disease biotechs – BioCryst Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. – are merging in an all-stock transaction to create a larger firm that will have a stronger mid- and late-stage pipeline, an R&D organization with expertise in small molecules and oligonucleotides, and a significant stockpile of cash.

Together, the to-be-named new company will have novel, orally administered Phase III and Phase II candidates for hereditary angioedema (HAE), a Phase III immuno-oncology candidate and a Phase II asset for dermatomyositis